DNTH
Dianthus Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.73B
P/E Ratio
—
EPS
$-4.23
Beta
0.09
52W High
$96.50
52W Low
$16.64
50-Day MA
$86.01
200-Day MA
$51.93
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $1.34M |
| Gross Profit (TTM) | $1.34M |
| EBITDA | $-191.17M |
| Operating Margin | -10050.00% |
| Return on Equity | -22.70% |
| Return on Assets | -15.00% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $22.01 |
| Price-to-Book | 3.93 |
| Price-to-Sales (TTM) | 3538.57 |
| EV/Revenue | 2704.95 |
| EV/EBITDA | -7.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -60.20% |
| Shares Outstanding | $54.67M |
| Float | $54.60M |
| % Insiders | 0.13% |
| % Institutions | 116.03% |
Historical Volatility
HV 10-Day
35.10%
HV 20-Day
40.83%
HV 30-Day
39.69%
HV 60-Day
63.46%
HV Rank
6.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($125.83 target)
16
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026